Complete financial analysis of Quotient Limited (QTNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quotient Limited, a leading company in the Medical – Devices industry within the Healthcare sector.
- SAMWONSTEEL Co.,Ltd. (023000.KS) Income Statement Analysis – Financial Results
- Kadem Sustainable Impact Corporation (KSICU) Income Statement Analysis – Financial Results
- CLASS ACCELERATION CORP C/WTS 3 (CLAS-WT) Income Statement Analysis – Financial Results
- Actinium Pharmaceuticals, Inc. (ATNM) Income Statement Analysis – Financial Results
- Peugeot Invest Société anonyme (SFFFF) Income Statement Analysis – Financial Results
Quotient Limited (QTNT)
About Quotient Limited
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.51M | 43.38M | 32.66M | 29.13M | 24.73M | 22.23M | 18.52M | 18.41M | 19.76M | 14.37M | 12.22M | 10.03M |
| Cost of Revenue | 23.57M | 20.07M | 17.80M | 17.23M | 10.47M | 10.84M | 9.66M | 9.76M | 8.41M | 7.17M | 6.75M | 5.63M |
| Gross Profit | 14.95M | 23.31M | 14.86M | 11.90M | 14.26M | 11.38M | 8.86M | 8.65M | 11.35M | 7.20M | 5.47M | 4.41M |
| Gross Profit Ratio | 38.80% | 53.72% | 45.49% | 40.86% | 57.66% | 51.21% | 47.86% | 46.96% | 57.45% | 50.11% | 44.77% | 43.91% |
| Research & Development | 58.69M | 54.17M | 53.74M | 50.68M | 51.20M | 57.06M | 28.78M | 19.22M | 8.07M | 2.62M | 1.75M | 1.70M |
| General & Administrative | 49.06M | 41.80M | 31.95M | 31.55M | 25.70M | 22.72M | 26.10M | 16.39M | 9.47M | 6.82M | 6.01M | 5.35M |
| Selling & Marketing | 11.02M | 9.85M | 9.85M | 8.64M | 7.35M | 5.66M | 3.07M | 2.75M | 2.71M | 2.25M | 1.67M | 1.46M |
| SG&A | 60.08M | 51.65M | 41.80M | 40.18M | 33.05M | 28.38M | 29.17M | 19.14M | 12.18M | 9.08M | 7.69M | 6.80M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 118.77M | 105.81M | 95.55M | 90.86M | 84.25M | 85.44M | 57.95M | 38.36M | 20.24M | 11.69M | 9.43M | 8.51M |
| Cost & Expenses | 142.34M | 125.89M | 113.35M | 108.09M | 94.72M | 96.29M | 67.61M | 48.12M | 28.65M | 18.86M | 16.18M | 14.13M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 57.00K | 87.00K | 0.00 |
| Interest Expense | 31.95M | 25.92M | 23.86M | 20.02M | 15.37M | 9.90M | 4.15M | 2.32M | 1.08M | 291.00K | 427.00K | 312.00K |
| Depreciation & Amortization | 7.42M | 8.62M | 12.28M | 12.77M | 10.41M | 9.46M | 2.95M | 1.68M | 622.00K | 691.00K | 989.00K | 980.00K |
| EBITDA | -84.80M | -72.01M | -65.98M | -72.56M | -57.22M | -65.71M | -26.78M | -55.07M | -8.47M | -3.73M | -3.06M | -3.33M |
| EBITDA Ratio | -220.17% | -165.99% | -202.04% | -249.05% | -231.35% | -295.61% | -144.60% | -299.15% | -42.86% | -25.97% | -25.02% | -33.18% |
| Operating Income | -92.22M | -82.51M | -80.69M | -78.96M | -69.99M | -74.06M | -49.09M | -29.71M | -8.89M | -4.49M | -3.96M | -4.10M |
| Operating Income Ratio | -239.43% | -190.20% | -247.09% | -271.01% | -282.99% | -333.19% | -265.03% | -161.42% | -45.01% | -31.25% | -32.44% | -40.85% |
| Total Other Income/Expenses | -31.95M | -24.04M | -21.42M | -26.39M | -13.00M | -11.01M | 15.21M | -29.35M | -1.27M | -223.00K | -509.00K | -522.00K |
| Income Before Tax | -124.17M | -106.54M | -102.11M | -105.34M | -82.99M | -85.07M | -33.88M | -59.06M | -10.17M | -4.71M | -4.47M | -4.62M |
| Income Before Tax Ratio | -322.40% | -245.61% | -312.69% | -361.58% | -335.55% | -382.73% | -182.91% | -320.83% | -51.46% | -32.80% | -36.61% | -46.05% |
| Income Tax Expense | 961.00K | 1.93M | 661.00K | 44.00K | -649.00K | -1.11M | 19.36M | -27.03M | -197.00K | 68.00K | -82.00K | -210.00K |
| Net Income | -125.13M | -108.47M | -102.77M | -105.39M | -82.34M | -85.07M | -33.88M | -59.06M | -10.17M | -4.71M | -4.47M | -4.62M |
| Net Income Ratio | -324.89% | -250.05% | -314.71% | -361.73% | -332.92% | -382.73% | -182.91% | -320.83% | -51.46% | -32.80% | -36.61% | -46.05% |
| EPS | -49.11 | -47.35 | -57.41 | -76.82 | -80.65 | -120.90 | -69.29 | -159.91 | -22.13 | -13.12 | -12.45 | -12.86 |
| EPS Diluted | -49.11 | -47.35 | -57.41 | -76.82 | -80.65 | -120.90 | -69.29 | -159.91 | -22.13 | -13.12 | -12.45 | -12.86 |
| Weighted Avg Shares Out | 2.55M | 2.29M | 1.79M | 1.37M | 1.02M | 703.64K | 488.95K | 369.34K | 459.41K | 359.41K | 359.41K | 359.41K |
| Weighted Avg Shares Out (Dil) | 2.55M | 2.29M | 1.79M | 1.37M | 1.02M | 703.64K | 488.95K | 369.34K | 459.41K | 359.41K | 359.41K | 359.41K |
Quotient Limited Provides Fourth Quarter and Full Year Fiscal 2021 Results and provides Business Update
Quotient Limited to Participate in Upcoming Investor Conferences
MosaiQ by Quotient Wins Prestigious Red Dot Design Award
Quotient Limited Reports Further Enhanced Multimodal Capabilities of the MosaiQ Technology
Quotient Limited Announces Equity Awards
Quotient Limited Announces Manuel Mendez as Chief Executive Officer
Quotient Limited Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Quotient Limited (QTNT) CEO Franz Walt on Q3 2021 Results - Earnings Call Transcript
Quotient (QTNT) Reports Q3 Loss, Tops Revenue Estimates
Quotient Limited Reports Third Quarter Fiscal 2021 Results and Business Update
Source: https://incomestatements.info
Category: Stock Reports